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Based on clinical trials showing the efficacy to reduce vertebral and non-
vertebral fractures, strontium ranelate (SrR) has been approved in several
countries for the treatment of postmenopausal osteoporosis. Hence, it is of
special clinical interest to elucidate how the Sr uptake is influenced by dietary
Ca deficiency as well as by the formula of Sr administration, SrR versus
strontium chloride (SrCl2). Three-month-old ovariectomized rats were treated
for 90 days with doses of 25 mg kg1 d1 and 150 mg kg1 d1 of SrR or SrCl2
at low (0.1% Ca) or normal (1.19% Ca) Ca diet. Vertebral bone tissue was
analysed by confocal synchrotron-radiation-induced micro X-ray fluorescence
and by backscattered electron imaging. Principal component analysis and
k-means clustering of the acquired elemental maps of Ca and Sr revealed that
the newly formed bone exhibited the highest Sr fractions and that low Ca diet
increased the Sr uptake by a factor of three to four. Furthermore, Sr uptake in
bone of the SrCl2-treated animals was generally lower compared with SrR. The
study clearly shows that inadequate nutritional calcium intake significantly
increases uptake of Sr in serum as well as in trabecular bone matrix. This
indicates that nutritional calcium intake as well as serum Ca levels are important
regulators of any Sr treatment.
Keywords: strontium ranelate; strontium chloride; dietary calcium; ovariectomized rats;
SR m-XRF; qBEI; elemental mapping; principal component analysis; k-means clustering.
1. Introduction
Strontium has been studied in the context of a possible ther-
apeutic agent for skeletal diseases for more than half a century
(Marie et al., 1985; McCaslin & Janes, 1959; Shorr & Carter,
1952; Skoryna, 1981; Storey, 1962; Grynpas & Marie, 1990).
Based on results of recent clinical trials showing reduced
vertebral and non-vertebral fracture risk, strontium ranelate
(SrR) is now approved in several countries for the treatment
of postmenopausal osteoporosis (Reginster et al., 2008).
Studies on potential mechanisms for SrR antifracture efficacy
include effects on bone microarchitecture and bone re-
modeling balance (Ammann et al., 2007; Fuchs et al., 2008a;
Ma et al., 2011) and Sr interaction with the calcium-sensing
receptor of bone cells (Brennan et al., 2009). Recent studies
investigated Sr accumulation and storage in bone and whether
Sr has an impact on the intrinsic material properties of bone
(Li et al., 2010; Roschger et al., 2010). It should be emphasized
that Sr, with its about two-fold larger atomic weight compared
with Ca, interferes with the measurement of bone mineral
density (BMD), which is a clinically important surrogate
parameter for antifracture effectiveness. Consequently, in Sr-
treated patients, changes in BMD occur not only due to
changes in bone volume and/or mineral content but also due
to Sr uptake, which makes reliable interpretation of osteo-
densitometry difficult (Ba¨renholdt et al., 2009; Blake &
Fogelman, 2007; Kendler et al., 2009). Bearing in mind that, in
vertebrates, 99% of whole body Ca and Sr is located in bone
(Dahl et al., 2001), the amount incorporated is positively
correlated with serum levels of Sr as numerous studies have
shown (Dahl et al., 2001; Fuchs et al., 2008a; Li et al., 2010;
Roschger et al., 2010; Boivin et al., 1996; Farlay et al., 2005). In
addition, it was recently demonstrated that Sr is preferentially
located in the new bone formed during Sr treatment and only
marginally located in the pre-existing bone matrix (Fuchs et
al., 2008a; Li et al., 2010; Roschger et al., 2010). Sr atoms are
incorporated into the crystal lattice of the bone hydroxy-
apatite by ionic substitution of calcium (Li et al., 2010).
A recent study in ovariectomized (OVX) rats (Fuchs et al.,
2008a) determined the effects of high (150 mg kg1 d1) and
low (25 mg kg1 d1) dose SrR on bone histomorphometric
indices, mechanical properties and Sr uptake. Furthermore,
the role of dietary calcium in modulating the effect of SrR on
the skeleton was examined by feeding rats either a normal
(1.19% Ca) or a low calcium diet (0.1% Ca). The concentra-
tion and distribution of Ca and Sr in cortical bone tissue of the
tibial midshaft region was determined using a synchrotron-
radiation-induced micro X-ray fluorescence (SR m-XRF)
method. Animals treated with high-dose SrR had significantly
higher Sr incorporation, regardless of Ca intake. However,
compared with the normal Ca diet, the low Ca diet increased
the incorporation of Sr into the bone for low- and high-dose
SrR groups. All animals treated with SrR had a higher Sr
fraction at the periosteal bone surface (newly formed bone
regions) compared with intracortical bone regions (older
bone).
The aim of the present study was to expand these investi-
gations to the administration of Sr by SrCl2 as well as SrR with
low and normal Ca diets. A further aim was to extend the
analysis for Sr uptake and distribution into the geometrical
more complex trabecular bone compartment of the vertebrae,
which contains bone marrow, in contrast to tibial periosteal
bone. For this purpose, an advanced state-of-the-art confocal
SR m-XRF technique was used. Quantitative backscattered
electron imaging (qBEI) was employed to select regions of
interest for SR m-XRF. In addition, principal component
analysis and k-means clustering were used to analyze the
elemental maps and to separate regions with typical Sr to Ca
fractions within the samples. This is the first time that such a
technique of analysis of elemental maps has been applied to
the study of bone tissue.
2. Methods and materials
2.1. Bone samples
We analyzed bone samples from the previously reported
study (Fuchs et al., 2008a) on Sr treatment in three-month-old
OVX Sprague-Dawley rats. The animal study was approved
by Indiana University’s Institutional Animal Care and Use
Committee. OVX rats were randomized by body mass three
weeks post surgery and divided into eight different treatment
regimens: low (25 mg kg1 d1) and high (150 mg kg1 d1)
dose SrR with low (0.1% Ca) and normal (1.19% Ca) dietary
Ca; low (25 mg kg1 d1) and high (150 mg kg1 d1) SrCl2
with low (0.1% Ca) and normal (1.19% Ca) dietary Ca. The
Sr2+ ion equivalents for SrR with the chemical formula
C12H6N2O8SSr2 (513.49 g mol
1) were 8.5 mg kg1 d1 and
51 mg kg1 d1, and for SrCl2 with the chemical formula
SrCl26(H2O) (266.62 g mol
1) were 9.4 mg kg1 d1 and 56 mg
kg1 d1, for the low and high Sr doses, respectively. SHAM
operated and untreated OVX rats fed a normal Ca diet served
as controls. Animals were treated daily for 90 d. According to
previously published Sr serum level data (Fuchs et al., 2008a)
the different treatments regimes led to the following mean Sr
serum levels: 22.7 and 23.3 ng ml1 for untreated SHAM and
OVX, 2226.7 and 293.5 ng ml1 for 25 mg kg1 d1 SrR
treatment at 0.1% and 1.19% Ca diet, respectively, 12611.1
and 1746.0 ng ml1 for 150 mg kg1 d1 SrR treatment at 0.1%
and 0.19% Ca diet, respectively. One L3 vertebra from each
group was used for analysis, while all the measurements of the
bone samples were performed blinded to the treatment
(Table 1).
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Table 1
Sr2+ uptake of bone tissues analysed.
Data shown are median and range [min; max] obtained from the elemental maps performed for each bone tissue sample. N= number of maps per sample. Calcium
diet: 1.19% is normal, 0.1% is deficient. Sr/(Ca + Sr): values of cluster C4 (region of highest Sr fractions) representing the newly formed bone matrix (see also
Fig. 2). p-Values between the groups of single Sr/(Ca + Sr) outcomes of each bone sample. p-Values in parentheses means that the data of SrR and SrCl2 samples
were correspondingly pooled. none: non-treated with SrR or SrCl2; ns: not significant.
Experimental data p-Values between groups of maps
Sample (N)
Sr2+ doses
(mg kg1 d1)
Ca diet
(wt%) Sr/(Ca + Sr) (count rates)
Versus
control
Low versus
high Sr
Deficient versus
normal Ca
SrR versus
SrCl2
1c (3) SHAM none 1.19 0.0012 [0.0010; 0.0013]
2c (4) OVX none 1.19 0.0011 [0.0011; 0.0012] <0.01
3n (5) SrR 8.5 1.19 0.024 [0.020; 0.024] <0.01 ns
4n (4) SrCl2 9.4 1.19 0.02148 [0.018; 0.023] <0.05 <0.05 (<0.001)
5d (3) SrR 8.5 0.1 0.1015 [0.094; 0.109] <0.01 <0.05 (<0.001) ns
6d (4) SrCl2 9.4 0.1 0.085 [0.081; 0.095] <0.01 <0.05 (<0.001)
7n (4) SrR 51 1.19 0.140 [0.136; 0.153] <0.001 <0.01 (<0.001) <0.05
8n (8) SrCl2 56 1.19 0.130 [0.105; 0.138] <0.05 0.1 (<0.001) 0.05 (<0.001)
9d (3) SrR 51 0.1 0.4252 [0.418; 0.435] <0.01 <0.05 (<0.001) <0.01 (<0.001) 0.057
10d (4) SrCl2 56 0.1 0.3528 [0.322; 0.378]
Vertebrae were fixed in 70% ethanol, dehydrated through
a graded series of ethanol, and embedded undecalcified in
polymethylmethacrylate (PMMA). About 5 mm-thick blocks
containing a sagittal vertebral bone section were obtained
using a low-speed diamond saw (Buehler Isomet, Lake Pluff,
USA). The section surfaces were ground by sand paper and
subsequently polished using a diamond suspension (3 and
1 mm grain size) on a precision polishing device (PM5 Logi-
tech, Glasgow, Scotland). The sample surface was carbon
coated (Agar SEM Carbon Coater, Stansted, UK) prior to
qBEI and subsequent SR m-XRF analysis.
2.2. qBEI
The intensity of electrons backscattered from the sample
surface is proportional to the average atomic number of the
target material. For trabecular bone tissue from the rat
vertebral bodies, the weight fraction of Ca (atomic numberZ =
20) predominantly influences the material contrast of the bone
tissue, which is composed of an organic phase (Z = 6) and a
hydroxyapatite mineral phase (Z = 14). Details of the tech-
nique can be found elsewhere (Fratzl-Zelman et al., 2009;
Roschger et al., 1998, 2008). qBEI images the local mineral
content with a spatial resolution of <1 mm. Thus, areas with
high backscattered electron intensities, i.e. bright gray levels in
the image, represent mineralized matrix with high Ca content,
whereas areas with low intensities, i.e. dark gray levels, indi-
cate low Ca content. The method cannot distinguish between a
local increase in gray levels caused by Sr uptake (Z = 38)
versus Ca. Hence, element-specific methods had to be used to
localize and quantify the Sr uptake.
qBEI was performed in a digital scanning electron micro-
scope (DSM 962, Zeiss, Oberkochen, Germany) equipped
with a four-quadrant semiconductor backscattered electron
detector. The microscope was operated at an acceleration
voltage of 20 kV, the working distance kept at 15 mm, and the
probe current was maintained at 110 pA. The entire trabecular
bone area was imaged by qBEI using a pixel resolution of
1 mm. From these qBEI gray-scale images, areas of interest
(ROI) have been selected for elemental mapping by confocal
SR m-XRF. The selection criteria were such that the ROI
contained trabecular bone features with bone regions
(packets) of low and light gray levels representing the co-
existence of young and older bone matrix (Fig. 1).
2.3. SR m-XRF analysis
Micro-XRF is based on the detection of characteristic
X-rays induced by high-energy primary photons (Van Grieken
& Markowicz, 2002). Using synchrotron radiation as exciting
X-ray source, the outstanding properties of synchrotron
radiation, including high photon flux, natural collimation,
polarization and the possibility to select the energy of the
primary photons, greatly increase the spatial resolution and
detection limits (fg-range, mm-range) of the m-XRF. In
combination with confocal geometry, high-sensitive element
mapping with spatial resolution in the micrometer range can
be performed (Zoeger et al., 2006, 2008). More details on
confocal SR m-XRF are provided elsewhere (Zoeger et al.,
2006, 2008; Janssens et al., 2004; Kanngießer et al., 2003; Vincze
et al., 2004; Simon et al., 2007).
In the present study the confocal SR m-XRF set-up was
installed at the FLUO beamline at ANKA (Karlsruhe,
Germany) (Simon et al., 2003). Two polycapillary half lenses
with overlapping focal spots were used. The set-up was tested
with reference samples revealing a beam size of 10 mm 
10 mm and a depth resolution of 12 mm at 14.2 keV (SrK). To
achieve optimal excitation conditions for Sr K-lines, the
excitation energy was adjusted to 17.7 keV by means of a W/Si
multilayer monochromator. The detector was a 50 mm2 silicon
drift detector (Vortex, SII NanoTechnology, USA) connected
to a digital signal processor (Saturn, XIA, USA). At a
measuring time of 1 s per spectrum the sensitivity of the
method was sufficient for detection of the natural Sr content
of bone (about 0.1 wt%).
The scans on the sample surface were performed as area
scans ranging from 300 mm  300 mm up to 850 mm  850 mm
depending on the ROI on the sample. For each ROI, several
depth scans were performed to determine the correct
measurement plane. The optimal depth is where the Ca K
intensity of the depth scans reaches its maximum. This
procedure ensures that the measurement plane is parallel to
the sample surface and so all measured voxels are at the same
depth within the sample. The acquired spectra were processed
using the microxrf2 software package (B. Vekemans, XMI,
Universiteit Gent) installed at the beamline to generate the
elemental maps. Peak deconvolution and subtraction of the
spectral background was carried out with the AXIL (Van
Espen et al., 1986) module implemented in this package. The
resulting maps of net intensities were normalized to counts per
second and 100 mA storage ring current, and were converted
to 8-bit grayscale images.
2.4. Principal component analysis and k-means clustering
Owing to the large number of maps (up to eight scans per
sample and ten samples resulting in a total of 42 scans), an
automated image data analysis technique was used to extract
the typical Sr to Ca K-lines counts fractions of the bone
areas. This method was originally established and described by
Vekemans et al. (1997). Like all other clustering methods
k-means clustering (KMC) allows calculation of the degree of
similarity (or distance in property space) between two objects
to be clustered. In the presented case the objects are pixels
(index i) and their properties are either X-ray intensities
derived from the spectrum of pixel i or the score values of that
pixel on the equivalent principal component axes. The simi-
larity measure between two pixels A and B can then be
expressed as Euclidian distance in property space. The result
of such a clustering (after principal component pre-treatment)
is displayed in Fig. 2. The pre-treatment using principal
component analysis (PCA) is not indispensable but allows for
more rapid processing of the data set by eliminating noise and
reducing dimensionality prior to the clustering (e.g. if more
than two pixel properties, here X-ray intensities of specific
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elements, are investigated). The clustering algorithm could
also be applied to the X-ray maps directly; however, in this
case only images should be used showing high contrasts (low
noise) which are appropriately scaled to each other. The
approach using PCA to pre-process the data before KMC
takes care of the image selection (noise removal) and scaling
problem.
A number of four clusters proved to be sufficient for proper
KMC results, as more than four clusters led to empty clusters
in the result. PCA and KMC were performed for all samples.
The classification of the clusters C1, C2, C3, C4 was performed
by considering their Sr counts fraction values [Sr/(Sr + Ca)]
(Fig. 2). The median and range [min; max] (Table 1) of the Sr
to Ca counts fraction values of cluster C4 from the individual
elemental maps per bone tissue sample was determined.
Cluster C4 was the region of highest Sr counts fractions
representing the newly formed bone matrix (Fig. 2). Mann-
Whitney tests between the groups of single Sr/(Ca + Sr)
outcomes from each bone sample were performed to deter-
mine the significance levels (p-values) of the differences. A
value of p < 0.05 was considered as significant. Additionally,
the significance of differences between low and high Sr doses
or deficient and normal Ca content were also evaluated
independently for type of administration (SrR and SrCl2). In
these cases the outcomes of SrR and SrCl2 samples were
correspondingly pooled (Table 1).
3. Results
Sr levels were measured in vertebral trabecular bone in rats
treated with low- and high-dose SrR and SrCl2 with normal
and low Ca diet, and in untreated controls. Based on qBEI
images, areas containing newly formed bone were selected for
confocal SR m-XRF. Examples of maps (Ca, Sr and corre-
sponding qBEI) for five treatment groups are shown in Fig. 1.
research papers
838 Bernhard Pemmer et al.  Strontium uptake in trabecular bone J. Synchrotron Rad. (2011). 18, 835–841
Figure 2
Example of a PCA + KMC analysis. The scan was performed on a sample
(9d of Table 1) with high-dose SrR treatment at deficient Ca diet. (a)
Score plot of principle components PC1 versus PC2 derived from a plot of
Ca versus Sr intensities by linear transformation exhibiting a new set of
mutually orthogonal axes. The PC1 axis represents the direction of
constant Sr/Ca ratios. The PC2 axis represents the direction of changing
Sr/Ca ratios. The KMC analysis of the PCA score plot used four clusters
(k = 4), color-coded red, green, pink and blue; the crosses in circles are
centroids of clusters C1, C2, C3, C4. The meaning of the clusters can be
explained by generating binary images, where all pixels corresponding to
a certain cluster are displayed in white (b). (b) Binary images produced
according to the cluster data: image C1 shows the distribution of pixels
clustered in C1 (red) and corresponds to the background/bone-marrow
space, where both Ca and Sr concentrations are zero. Image C2 (pixels
from cluster C2, green) highlights areas of old bone showing a low Sr to
Ca fraction, while image C3 (pixels clustered in C3, purple) contains
pixels representing the rim region of the bone. Finally, image C4, which
contains all pixels of cluster C4 (cyan), displays pixels of highest Sr to Ca
fraction, corresponding to areas of young bone.
Figure 1
Examples of qBEI images and the corresponding SR m-XRF elemental
maps of calcium (Ca) and strontium (Sr) based on Ca K and Sr K
fluorescence lines, respectively, from bone samples of animals untreated
and treated by SrR or SrCl2: (a) untreated, (b) low Sr dose at normal Ca
diet, (c) low Sr dose at deficient Ca diet, (d) high Sr dose at normal Ca,
and (e) high Sr dose at deficient Ca. The pixel size of the SR m-XRF
elemental maps is 10 mm  10 mm with a depth resolution of 12 mm at Sr
K (14.2 keV). The color-coded X-ray intensities (counts s1) are scaled
from minimum to maximum. qBEI shows young bone packets (less
mineralized) as darker, and older bone packets as well as residual
cartilage (higher mineralized) as brighter gray levels.
Comparing the elemental maps of Sr with the corre-
sponding qBEI images revealed that, with Sr administration,
Sr was mainly incorporated into the newly formed bone matrix
predominantly adjacent to the bone surface (darker gray-
levels in qBEI), and was marginally incorporated into the old
higher mineralized bone packets (brighter gray-levels in the
qBEI images). Untreated controls (Fig. 1a) showed a homo-
geneous Sr distribution of natural Sr, with the lowest level of
Sr count rates. This indicates that, with natural intake over
time, Sr was associated with all the bone packets equally.
Considering the maximum of Sr count rates in the Sr maps
as indicated by color-coded intensity scales (Fig. 1a–1e), bone
samples from different Sr treatment regimes show Sr count
rates ascending from low Sr dose with normal Ca diet followed
by low Sr with low Ca diet, high Sr dose with normal Ca diet,
and finally by high Sr dose with low Ca diet.
PCA and KMC of the elemental maps (Fig. 2a) assigned all
samples consistently into the ten different treatments. The
cluster (C4) with the highest Sr counts fraction Sr/(Ca + Sr)
values representing the newly formed bone was used for the
assignment, because it showed the largest differences between
the treatment groups (Fig. 2b). The C4 outcomes are shown
in Table 1. The increase in the Sr to Ca counts fraction with
normal Ca diet was 20.8 times for low SrR doses and 121.7
times for high SrR doses compared with untreated animals.
Low Ca diet additionally increased the Sr counts fraction 89
times for low SrR dose and 365 times for high SrR dose
compared with normal Ca diet. In Fig. 3 the effect of low Ca
diet on Sr uptake is clearly demonstrated. Further, the direct
relationship between increase in Sr uptake and that of Sr
serum levels can be seen.
Sr uptake in cluster C4 for low Sr dose and high Sr dose was
lower for SrCl2 versus SrR (7.7% and 9.1%, respectively,
with normal Ca diet; 20.4% and 19.8%, respectively, with
low Ca diet), but differences were only partly significant
(Table 1).
4. Discussion
In this analysis SR m-XRF combined with qBEI together with
PCA and KMC were used to evaluate Sr uptake into bone
with different levels of Sr intake and dietary Ca intake.
Analysis of the Sr to Ca fractions showed that Sr uptake in
newly formed bone increases with increasing Sr dose. Low
dietary Ca further elevated Sr uptake. Sr uptake in bone was
slightly higher with SrR compared with SrCl2 even though the
Sr2+ equivalent in SrCl2 was 10% higher than in SrR.
This is the first time that PCA and KMC have been applied
to elemental maps from bone tissue to identify regions of
characteristic elemental fractions. An advantage of this
method is that it is mathematically objective and cannot be
biased by interaction with the observer. Also the observer
needs no specialized knowledge on the microscopic appear-
ance of the elemental maps. As a result this procedure is fast,
can handle a large number of maps, and can be expanded to
investigate relations among more than two elements. The
present analysis of the bone tissue regions with a maximum in
Sr to Ca counts fraction consistently and correctly identified
tissue from non-treated and from all animals treated differ-
ently with the eight combinations of Sr treatment and
dietary Ca.
4.1. Ca diet versus Sr uptake
Low Ca significantly increased (three to four times, Table 1)
the Sr to Ca counts fraction in the C4 cluster identified by
qBEI imaging as newly formed bone, i.e. regions with low Ca
content predominantly at the bone surface. In this context it is
interesting how the serum levels were influenced by dietary
Ca, because the serum level of Sr determines how much Sr is
incorporated in the HA lattice during bone formation (Li et
al., 2010; Roschger et al., 2010). As previously reported (Fuchs
et al., 2008a), these rats treated with 25 or 150 mg kg1 d1 of
SrR and fed the low calcium diet (0.1% Ca) showed increases
of more than seven times in serum Sr levels compared with
rats fed the normal calcium diet (1.19% Ca). Such an effect of
nutritional Ca deficiency might be of importance concerning
safety issues of Sr treatment in patients with osteoporosis.
Normal serum Ca levels, and adequate Ca and vitamin D
intake, must be a prerequisite of any osteoporosis treatment.
Low serum Ca levels would result in higher uptake of Sr,
which can induce osteomalacia and mineralization defects
(Storey, 1962; Omdahl & DeLuca, 1971; Sobel et al., 1935).
4.2. SrR versus SrCl2
We also compared Sr uptake in bone with administration of
two different forms of Sr (SrR and SrCl2). At both Sr
2+ doses,
low and high, the Sr uptake in the new bone matrix was higher
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Figure 3
Influence of Ca diet on Sr uptake as quantified by cluster C4 centroid
values indicated by green (normal Ca diet) and red bars (deficient Ca
diet), respectively, whereby differences between SrR and SrCl2 are
distinguished by intense and light color. The increase in Sr uptake (height
of the bars) was in parallel with the increase in Sr serum levels. For each
sample, median and range (error bars) resulting from all maps recorded
are indicated. Significance levels as obtained by Mann-Whitney tests:
* p < 0.05. *** p < 0.001.  p = 0.057.
with SrR compared with SrCl2, even though the Sr
2+ equiva-
lent with SrCl2 was 10% higher than with SrR. For the normal
Ca diet it was about 8% higher, while for the low Ca diet it was
20% higher. The results suggest that, when Sr treatment
occurs at normal dietary Ca levels, SrR promotes greater
uptake to bone compared with SrCl2. However, care has to be
taken for adequate Ca serum levels, because SrR might deliver
too much Sr into the serum in the case of Ca deficiency.
4.3. Limitations
The study was designed as a pilot study for testing the
sensitivity to detect spatially resolved Sr in bone after
different Sr treatment regimes using a special confocal SR m-
XRF set-up. For this purpose we analyzed just one vertebral
bone sample per group from ten groups; two from untreated
animals (SHAM and OVX) and eight from animals of
different treatment regimens (low and high Sr as SrR or SrCl2
combined with normal or low dietary Ca). However, the
consistency in relationship between sample outcome and
treatment regime, as well as agreement with the previous
analysis of the tibial/periosteal bone (n = 10 per group) (Fuchs
et al., 2008a), suggests that the one tissue/group analyzed in
this study was representative of its treatment group. Although
several numerical differences were large, many were not
statistically significant. This is likely to be due to the limited
number of scans per bone tissue (in majority three to four
scans).
Another limitation is that the reported Sr and Ca concen-
trations are not given in absolute values (wt%), but always in
fractions of Sr to Ca X-ray peak count rates. Unfortunately,
there are no suitable reference standards for this novel
experimental set-up that would have allowed calculation of
absolute Sr and Ca concentrations from the X-ray count rates.
Differences in sensitivity of the system to detect Ca and Sr,
and differences in matrix effects between Ca K and Sr K
X-rays make it difficult to generate suitable reference stan-
dards.
Sr serum concentrations in this study were lower or
encompassed levels (12611 ng ml1, or 185 mmol L1)
comparable with those produced by SrR treatment of post-
menopausal osteoporosis (10560 ng ml1, or 120.4 mmol L1)
(Roschger et al., 2010; Fuchs et al., 2008b). In this human study
an atomic fraction for Sr to Ca of 5% was found (Roschger et
al., 2010; Li et al., 2010), but extrapolation from animals to
humans and vice versa should be made with caution.
5. Conclusions
In conclusion, dietary and serum levels of Ca are important
determinants of serum Sr levels and Sr uptake into bone with
SrR treatment for osteoporosis. To avoid higher uptake rates
of Sr and improve safety in patients being treated with SrR,
adequate Ca and vitamin D intake is essential.
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